Related Articles
JAK2 V617F detected in two B‑cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome‑negative myeloproliferative neoplasms: A report of two cases
Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report)
Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1‑negative myeloproliferative neoplasms
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up
pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms